Close mobile menu×
Close mobile menu

Catherine Ann Shu, MD

Board Certifications: 
Internal Medicine, Medical Oncology
Expertise in: 
Esophageal Cancer, Lung Cancer
Accepting New Patients
Profile Headshot

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Internal Medicine
  • Medical Oncology

Clinical Expertise

  • Thoracic Cancer
  • Thoracic Lung Cases
  • Thoracic Oncology
  • Thymoma

Education & Training

  • MD, Columbia University College of Physicians and Surgeons
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center

About Catherine Shu

Dr. Catherine Shu is a board-certified medical oncologist specializing in the treatment of thoracic cancers, especially lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow. She currently serves as the Clinical Director of the Thoracic Medical Oncology Service.

She has presented her work at numerous national conferences and was awarded an American Society for Clinical Oncology (ASCO) Merit Award for her research. She is particularly interested in immunotherapy and its potential combinations with chemotherapeutics and targeted therapies, as well as novel agents.

Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Administrative Positions

  • Clinical Director, Thoracic Medical Oncology Service

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Mandarin

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Primary

Research

Grants

A BIOMARKER-DIRECTED PHASE 2 PLATFORM STUDY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED ON FIRST-LINE OSIMERTINIB THERAPY(ORCHARD) (P&S Industry Clinical Trial)

Mar 20 2020 - Mar 20 2025

A PHASE 1/1B STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF IMMUNOTHERAPY. COMBINATIONS IN PARTICIPANTS WITH LUNG CANCER (P&S Industry Clinical Trial)

Feb 25 2020 - Feb 25 2025

ANOPEN-LABEL, MULTI-CENTER ROLLOVER PROTOCOL FOR CONTINUED CHARACTERIZATION OF SAFETY AND TOLERABILITY FOR SUBJECTS WHO HAVE PARTICIPATED IN A NOVARTIS-SPONSORED SPARTALIZUMAB STUDY AS SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS. (P&S Industry Clinical Trial)

Jul 24 2019 - Jul 24 2024

APHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION STUDY OF JNJ-61186372, A HUMAN BISPECIFIC EGFR AND CMET ANTIBODY, IN SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (P&S Industry Clinical Trial)

Feb 1 2019 - Feb 1 2024

AMULTIARM, OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY TO EVALUATE NOVEL COMBINATION THERAPIES IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED EGFRM NSCLC (P&S Industry Clinical Trial)

Feb 26 2018 - Feb 26 2023

APHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE STUDY TO DETERMINE THE EFFICACY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB IN COMBINATION WITH PLATINUM- (P&S Industry Clinical Trial)

Aug 1 2017 - Aug 1 2022

A PHASE I STUDY EVALUATING THE SAFETY AND EFFICACY OF SGI-110 FOLLOWED BY COMBINED DURVALUMAB (MEDI4736) PLUS TREMELIMUMAB IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) (P&S Industry Clinical Trial)

Apr 17 2017 - Apr 17 2022

A PHASE I STUDY EVALUATING THE SAFETY AND EFFICACY OF SGI-110 FOLLOWED BY COMBINED DURVALUMAB (MEDI4736) PLUS TREMELIMUMAB IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) (P&S Industry Clinical Trial)

Apr 4 2017 - Apr 4 2022